New imaging agent spots hidden prostate cancer recurrence
NCT ID NCT04186845
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tested a new imaging agent called rhPSMA-7.3 (18F) for PET scans in 391 men with suspected prostate cancer recurrence based on rising PSA levels after initial treatment. The goal was to see how well the scan could detect where the cancer had returned. Results showed the scan accurately identified cancer locations, helping guide further treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CWZ
Nijmegen, 6532, Netherlands
-
Chesapeake Urology Research Associates
Towson, Maryland, 21204, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke University Medical Center
Durham, North Carolina, 27701, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
John Wayne Cancer Institute
Santa Monica, California, 90403, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
MD Anderson Hospital
Houston, Texas, 77054, United States
-
Maxima MC
Veldhoven, 5504 DB, Netherlands
-
MidLantic Urology
Philadelphia, Pennsylvania, 19004, United States
-
Montefiore Hospital
The Bronx, New York, 10461, United States
-
Mount Sinai Faculty Practice Associates
New York, New York, 10029, United States
-
Northshore University HealthSystem
Evanston, Illinois, 60201, United States
-
Northside Hospital
Austell, Georgia, 30342, United States
-
Queens Hospital Center (QHC - Queens Cancer Center
Jamaica, New York, 11432, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Stony Brook University
Stony Brook, New York, 11794, United States
-
Tower Urology
Los Angeles, California, 90048, United States
-
Turku University Hospital
Turku, FI-20520, Finland
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of California Irvine Medical Center (UCIMC)
Orange, California, 92868, United States
-
University of Michigan Ann Arbor
Ann Arbor, Michigan, 48109, United States
-
University of Virginia - Health Science Center
Charlottesville, Virginia, 22908, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.